TSE:TRIL - Trillium Therapeutics Stock Price, Price Target & More

C$8.93 -0.17 (-1.87 %)
(As of 04/22/2018 02:05 PM ET)
Previous CloseC$8.93
Today's RangeC$8.79 - C$9.15
52-Week RangeC$5.26 - C$16.80
Volume4,300 shs
Average Volume6,529 shs
Market CapitalizationC$124.24 million
P/E RatioN/A
Dividend YieldN/A

About Trillium Therapeutics (TSE:TRIL)

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-259.65%
Return on Assets-55.25%


Outstanding Shares13,147,000

How to Become a New Pot Stock Millionaire

Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."

Who are some of Trillium Therapeutics' key competitors?

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the folowing people:
  • Dr. Bjorn Johan Niclas Stiernholm, CEO, Pres & Director
  • Mr. James T. Parsons, Chief Financial Officer (Age 53)
  • Dr. Robert Uger Ph.D., Chief Scientific Officer
  • Dr. Penka Petrova Ph.D., Chief Devel. Officer
  • Dr. Eric L. Sievers, Sr. Clinical Advisor

Has Trillium Therapeutics been receiving favorable news coverage?

News headlines about TRIL stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trillium Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also assigned media headlines about the company an impact score of 46.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Trillium Therapeutics?

Shares of TRIL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately C$8.93.

How big of a company is Trillium Therapeutics?

Trillium Therapeutics has a market capitalization of C$124.24 million.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.

MarketBeat Community Rating for Trillium Therapeutics (TRIL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  102
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TRIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Trillium Therapeutics (TSE:TRIL) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/22/2016 forward)



Trillium Therapeutics (TSE:TRIL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Trillium Therapeutics (TSE TRIL) Insider Trading and Institutional Ownership History

Insider Trading History for Trillium Therapeutics (TSE:TRIL)

Trillium Therapeutics (TSE TRIL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/7/2017Gordon Edward ZelkoDirectorBuy93,000C$0.11C$10,230.00
6/30/2017Michael Bruno John Fr EnglandDirectorBuy54,000C$0.11C$5,940.00
6/15/2017John Parker MastersDirectorBuy50,000C$0.12C$6,000.00
6/6/2017Michael Bruno John Fr EnglandDirectorBuy19,000C$0.11C$2,090.00
5/2/2017Michael Bruno John Fr EnglandDirectorBuy100,000C$0.15C$15,000.00
4/20/2017Michael Bruno John Fr EnglandDirectorBuy11,500C$0.12C$1,380.00
4/19/2017Michael Bruno John Fr EnglandDirectorBuy50,000C$0.12C$6,000.00
4/13/2017Donald Laughlin MckinnonDirectorBuy20,000C$0.13C$2,600.00
4/10/2017Michael Bruno John Fr EnglandDirectorBuy12,000C$0.10C$1,200.00
3/27/2017Michael Bruno John Fr EnglandDirectorBuy5,000C$0.19C$950.00
3/22/2017Gordon Edward ZelkoDirectorBuy20,000C$0.10C$2,000.00
2/17/2017Michael Bruno John Fr EnglandDirectorBuy50,000C$0.12C$6,000.00
2/7/2017Gordon Edward ZelkoDirectorBuy50,000C$0.11C$5,500.00
1/31/2017Michael Bruno John Fr EnglandDirectorBuy20,000C$0.11C$2,200.00
(Data available from 1/1/2013 forward)


Trillium Therapeutics (TSE TRIL) News Headlines


SEC Filings

Trillium Therapeutics (TSE:TRIL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Trillium Therapeutics (TSE TRIL) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.